The following survey assessed patient views related to cytoreductive nephrectomy following publication of the results of the CARMENA trial, and were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019.

The survey found that overall survival should not be overestimated as the most important aim in an end-stage patient population. Patients might think differently about benefits, risks and value of surgical procedures then physicians.

Read more on ASCO University here